Despite skiing's complicated phrases, slang, and descriptors when it comes to snow and gear, the sport uses a rather simple ...

Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support ...

The city of Black Diamond has begun a fire protection and emergency services feasibility study in the midst of potentially ...

Black Diamond said Servier will develop and commercialize BDTX-4933, a small molecule designed by the Cambridge, Mass., company to address unmet medical needs in RAF/RAS-mutant solid tumors.

Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...

Wedbush reissued their outperform rating on shares of Black Diamond Therapeutics (NASDAQ:BDTX – Free Report) in a research ...

SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc. ...

Shares of NASDAQ BDTX opened at $1.72 on Tuesday. Black Diamond Therapeutics has a 1 year low of $1.59 and a 1 year high of $7.66. The stock’s 50-day simple moving average is $2.17 and its 200 ...

March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage ...